Literature DB >> 12447471

Oxidative stress in patients with primary pulmonary hypertension.

N L Irodova1, V Z Lankin, G K Konovalova, A G Kochetov, I E Chazova.   

Abstract

We studied the role of oxidative stress in the pathogenesis of primary pulmonary hypertension. In patients with primary pulmonary hypertension the content of malonic dialdehyde in the plasma was higher than in healthy volunteers (5.18 0.46 and 2.95 0.14 nmol/liter, respectively, p<0.01). However, glutathione peroxidase activity in the plasma decreased in these patients (0.50 0.17 vs. 1.19 0.14 U/ml in the control, p<0.05). By contrast, glutathione peroxidase activity in erythrocytes from patients surpassed the control (6.13 0.39 and 4.63 0.45 U/h hemoglobin). The increase in malonic dialdehyde content in the plasma and glutathione peroxidase activity in erythrocytes and the decrease in glutathione peroxidase activity in the plasma were most pronounced in patients with severe cardiac insufficiency and pulmonary hypertension. Our results indicate that antioxidant preparations improve the prognosis in patients with primary pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447471     DOI: 10.1023/a:1020238026534

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  15 in total

1.  Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  David J R Fulton; Xueyi Li; Zsuzsanna Bordan; Yusi Wang; Keyvan Mahboubi; R Daniel Rudic; Stephen Haigh; Feng Chen; Scott A Barman
Journal:  Antioxid Redox Signal       Date:  2019-03-29       Impact factor: 8.401

2.  Iron chelation inhibits the development of pulmonary vascular remodeling.

Authors:  Chi-Ming Wong; Ioana R Preston; Nicholas S Hill; Yuichiro J Suzuki
Journal:  Free Radic Biol Med       Date:  2012-08-25       Impact factor: 7.376

3.  Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension.

Authors:  Scott A Barman; Zsuzsanna Bordan; Robert Batori; Stephen Haigh; David J R Fulton
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Cholesterol-rich low density lipoproteins are also more oxidized.

Authors:  Vadim Lankin; Margus Viigimaa; Alla Tikhaze; Elena Kumskova; Galina Konovalova; Jelena Abina; Galina Zemtsovskaya; Tatyana Kotkina; Elena Yanushevskaya; Tatyana Vlasik
Journal:  Mol Cell Biochem       Date:  2011-06-07       Impact factor: 3.396

5.  Redox modulation of the fetal cardiovascular defence to hypoxaemia.

Authors:  A S Thakor; H G Richter; A D Kane; C Dunster; F J Kelly; L Poston; D A Giussani
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

Review 6.  Reactive oxygen species and antioxidants in pulmonary hypertension.

Authors:  Chi-Ming Wong; Geetanjali Bansal; Ludmila Pavlickova; Lucia Marcocci; Yuichiro J Suzuki
Journal:  Antioxid Redox Signal       Date:  2012-07-11       Impact factor: 8.401

Review 7.  Reactive oxygen species in pulmonary vascular remodeling.

Authors:  Saurabh Aggarwal; Christine M Gross; Shruti Sharma; Jeffrey R Fineman; Stephen M Black
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

Review 8.  Role of oxidized lipids in pulmonary arterial hypertension.

Authors:  Salil Sharma; Grégoire Ruffenach; Soban Umar; Negar Motayagheni; Srinivasa T Reddy; Mansoureh Eghbali
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

9.  Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment.

Authors:  Devashis Mukherjee; Girija G Konduri
Journal:  Compr Physiol       Date:  2021-06-30       Impact factor: 8.915

10.  Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability.

Authors:  Khrystyna Semen; Olha Yelisyeyeva; Iwona Jarocka-Karpowicz; Danylo Kaminskyy; Lyubomyr Solovey; Elzbieta Skrzydlewska; Ostap Yavorskyi
Journal:  Redox Biol       Date:  2015-11-22       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.